NASDAQ:SLP
Simulations Plus Stock News
$45.35
-0.100 (-0.220%)
At Close: Apr 30, 2024
Simulations Plus, Inc. (SLP) Q3 2023 Earnings Call Transcript
08:04pm, Thursday, 06'th Jul 2023
Simulations Plus, Inc. (NASDAQ:SLP ) Q3 2023 Earnings Conference Call July 6, 2023 5:00 PM ET Company Participants John Wilfong - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executiv
Simulations Plus (SLP) Q3 Earnings Miss Estimates
07:06pm, Thursday, 06'th Jul 2023
Simulations Plus (SLP) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.20 per share a year ago.
Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?
01:43pm, Monday, 03'rd Jul 2023
Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
04:06pm, Wednesday, 21'st Jun 2023
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call and webcast on July 6, 2023, at 5pm EDT to discuss the financial results from the 3rd quarter of FY2023.
7 Stocks Under $50 to Buy (and Never Sell)
06:31pm, Monday, 29'th May 2023
While it's a general rule of thumb that you get what you pay for, in the market, you can sneak in some overlooked compelling discounts, which might be the case with the below best affordable stocks to
WIX Rolls Out New Google Ads With Wix Feature for Users
08:25am, Friday, 19'th May 2023
: WIX's Google Ads with Wix feature will allow users to tailor ad settings according to their requirements. This will also help in creating ad content.
SONY Mulls Partial Spin-Off of Financial Services Segment
10:44am, Thursday, 18'th May 2023
SONY's assessment involves holding slightly less than 20% of the shares of Sony Financial Group which enable the latter to leverage the Sony brand.
WIX Q1 Earnings & Revenues Beat Estimates, Increase Y/Y
08:07am, Wednesday, 17'th May 2023
WIX Q1 performance benefits from strength in the Creative Subscriptions and Business Solutions segments. Cost-cutting efforts lead to significant margin improvement.
Simulations Plus: Overhyped With No Growth Left
12:38pm, Tuesday, 02'nd May 2023
Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growt
4 Low-Beta Tech Stocks to Hedge Against Market Uncertainty
12:10pm, Wednesday, 19'th Apr 2023
Investors can consider adding four low-beta tech stocks like TEAM, ZS, SLP and ASUR in their portfolios to hedge against a highly-volatile market.
Can Simulations Plus (SLP) Climb 53.66% to Reach the Level Wall Street Analysts Expect?
11:29am, Friday, 07'th Apr 2023
The mean of analysts' price targets for Simulations Plus (SLP) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Simulations Plus (SLP) Q2 Earnings Beat, Revenues Up Y/Y
09:11am, Thursday, 06'th Apr 2023
Simulations Plus' (SLP) Q2 results are driven by higher revenues in Software and Services business segments.
Simulations Plus, Inc. (SLP) Q2 2023 Earnings Call Transcript
08:09pm, Wednesday, 05'th Apr 2023
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Earnings Conference Call March 5, 2023 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - C
Simulations Plus (SLP) Surpasses Q2 Earnings Estimates
07:01pm, Wednesday, 05'th Apr 2023
Simulations Plus (SLP) delivered earnings and revenue surprises of 11.11% and 2.54%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?
Simulations Plus (SLP) Joins SACF to Develop Anticancer Drugs
08:26am, Wednesday, 29'th Mar 2023
Simulations Plus (SLP) will be working on the development of QSAR models by utilizing information available from both academic/patent literature and SACF to test effectiveness against MTHFD2.